Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Approval  ·  Weekly Digest - 28 March to 03 April 2026
ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer

Weekly Digest – April 2026 Weekly Digest – April 2026 27 March 2026: ENHERTU followed by THP approved in China as the first and only HER2 directed ADC for the neoadjuvant treatment of HER2 positive breast cancer ENHERTU in combination […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 28 March to 03 April 2026
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC

Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Zymeworks receives U.S. FDA Fast Track Designation for ZW191, an FRα-targeting ADC Zymeworks’ FRα-targeting ADC, ZW191, has received FDA Fast Track designation for patients with advanced or […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 28 March to 03 April 2026
RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials

Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: RemeGen’s dual-antibody ADC RC288 for the treatment of advanced malignant solid tumors has been officially approved for clinical trials RemeGen’s dual-target ADC, RC288, has received clinical trial […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 28 March to 03 April 2026
Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519

Weekly Digest – April 2026 Weekly Digest – April 2026 30 March 2026: Aktis Oncology announces FDA clearance of Investigational New Drug applications for AKY-2519 Aktis Oncology’s radiopharmaceutical candidate AKY-2519 has received IND clearance from the U.S. FDA, enabling the […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 28 March to 03 April 2026
Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy

Weekly Digest – April 2026 Weekly Digest – April 2026 01 April 2026: Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, Zocilurtatug Pelitecan, in combination with a bispecific T-cell Engager therapy Zai Lab […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 28 March to 03 April 2026
NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development

Weekly Digest – April 2026 Weekly Digest – April 2026 31 March 2026: NJ Bio and Ajinomoto Bio-Pharma Services partner to advance ADC and AOC development NJ Bio and Ajinomoto Bio-Pharma Services have entered into a research collaboration to expand […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 21 March to 27 March 2026
Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed or refractory large b-cell lymphoma Chugai has received approval in Japan (MHLW) […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 21 March to 27 March 2026
ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer Japan’s PMDA has approved a label update […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 21 March to 27 March 2026
ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors Japan’s MHLW has approved ENHERTU for […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 21 March to 27 March 2026
GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan

Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: GSK’s B7-H3-targeted ADC, Risvutatug rezetecan, granted Orphan Drug Designation for small-cell lung cancer in Japan GSK’s investigational B7-H3-targeted ADC, risvutatug rezetecan (Ris-Rez), has received ODD in Japan […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous171819202122232425Next ›Last »
Page 21 of 63


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id